Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: Implications for Parkinson's disease therapy

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 479-486

  Bharath, S ^a   Cochran, B C ^a   Hsu, M ^a   Liu, J ^b,c   Ames, B N ^b,c   Andersen, J K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Glutathione (GSH); Mitochondrial complex I; Parkinson's disease; R lipoic acid

Indexed keywords

GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; MITOCHONDRIAL ENZYME; THIOCTIC ACID; ANTIOXIDANT; BUTHIONINE SULFOXIMINE;

ANIMAL CELL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; MITOCHONDRIAL RESPIRATION; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANIMAL; ARTICLE; CELL STRAIN; CYTOPLASM; DRUG EFFECT; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; BUTHIONINE SULFOXIMINE; CYTOPLASM; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; MITOCHONDRIA; PARKINSON DISEASE; PC12 CELLS; RATS; THIOCTIC ACID;

EID: 0036778280     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00035-9     Document Type: Conference Paper

References (54)

1. Adams Jr, JD, Chang ML, Klaidman L. Parkinson's disease-redox mechanisms. Curr Med Chem 2001;8:809-14.
2. Ames BN. Micronutrients prevent cancer and aging. Toxicol Lett 1999;103:5-18.
3. Andersen JK, Mo JQ, Hom DG, Lee FY, Harnish P, Hamill RW, McNeill TH. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on murine nigrostriatal neurons. J Neurochem 1996;67:2164-71.
4. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992;31:119-30.
5. Burke RE. Parkinson's disease. In: Koliatos, Ratan RR, editors. Cell death and disease of the nervous system. Totowa (NJ): Humana Press, 1998. p. 459-75.
6. Bushtamante J, Lodge JK, Marcocci L, Tritschler HJ, Packer L, Rihn BH. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med 1998;24:1023-39.
7. Davey GP, Peuchen S, Clark JB. Energy thresholds in brain mitochondria: potential involvement in neurodegeneration. J Biol Chem 1998;273:12753-7.
8. Fuchs J, Packer L, Zimmer G. Lipoic acid in health and disease. New York: Marcel Dekker, 1997.
9. Greene L, Tischler A. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976;73:2424-8.
10. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-22.
11. Hagen TM, Ingersoll RT, Lykkesfeldt J, Liu J, Wehr CM, Vinarsky V, Barthlomew JC, Ames AB. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999;13:411-8.
12. Hagen TM, Vinarsky V, Wehr CM, Ames BN. (R)-alpha-lipoic acid reverses the age-associated increase in susceptibility of hepatocytes to tert-butylhydroperoxide both in vitro and in vivo. Antiox Redox Signal 2000;2:473-83.
13. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriat 2001;32:275-82.
14. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem 1985;44:117-27.
15. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohe L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 1997;6:321-38.
16. Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. Alternative Med Rev 2001;6:141-66.
17. Hillered L, Chan PH. Effects of arachidonic acid on respiratory activities in isolated brain mitochondria. J Neurosci Res 1988;19:94-100.
18. Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gammaglutamylcysteine synthetase. J Biol Chem 1993;268:19675-80.
19. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietz GJ. Improvement of insulin-stimulated glucose disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Endocrinol Diabetes 1996;104:284-8.
20. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 1993;146:6-13.
21. Jha N, Andersen JK. Loss of glutathione (GSH) in Parkinson's disease: how does GSH act to protect dopaminergic neurons of the substantia nigra? In: Pandalai SG, editor. Recent research developments in neurochemistry, Trivandrum (India): Research Signpost, 1999. p. 99-108.
22. Jha N, Jurma O, Lalli G, Liu Y, Pettusi EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson's disease. J Biol Chem 2000;275:26096-7001.
23. Jung CH, Thomas JA. S-glutathiolated hepatocyte proteins and insulin disulfides as substrates for reduction by glutaredoxin, thioredoxin, protein disulfide isomerase, and glutathione. Arch Biochem Biophys 1996;335:61-72.
24. Kagen VE, Serbinova EA, Forte T, Sata G, Packer L. Recycling of Vitamin E on human low density lipoproteins. J Lipid Res 1992;33:385-97.
25. Lee FYF, Siemann D, Allalunis-Turner J, Keng P. Glutathione content in humans and rodent cells in various phase of the cell cycle. Cancer Res 1988;48:3661-5.
26. Lenaz G, Bovina C, Castelluccio C, Fato R, Formiggini G, Genova ML, Marchetti M, Pich MM, Pallotti F, Parenti-Castelli G, Biagini G. Mitochondrial complex I defects in aging. Mol Cell Biochem 1997;174:329-33.
27. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with (R)-α-lipoic acid supplementation. FASEB J 1998;12:1183-9.
28. Maitra I, Serbinova E, Tritschler HJ, Packer L. Stereospecific effects of lipoic acid on buthionine-S,R-sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun 1996;221:422-9.
29. Matalon R, Stumpf DA, Michals K, Hart RD, Parks JK, Goodman SI. Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. J Pediatr 1984;104:65-9.
30. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263:17205-8.
31. Minchinton AI, Rojas A, Smith KA, Soranson JA, Shrieve DC, Jones NR, Bremner JC. Glutathione depletion in tissues after administration of buthionine sulfoximine. Int J Radic Oncol Biol Phys 1984;10:1261-4.
32. Packer L, Witt EH, Trischler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50.
33. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-78.
34. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 1997;104:661-77.
35. Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1988;67:269-74.
36. Ravindranath V, Reed DJ. Glutathione depletion and formation of glutathione-protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem Biophys Res Commun 1990;169:1075-9.
37. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative diseases. Curr Med Chem 2001;8:721-38.
38. Scott BC, Aruoma OI, Evans PJ, O'Neill C, Van Der Vliet A, Cross CE, Tritschler HJ, Halliwell B. Lipoic acid and dihydrolipoic acids as antioxidants: a critical evaluation. Free Radic Res Commun 1994;20:119-33.
39. Seelig GF, Meister A. Glutathione biosynthesis; gammaglutamylcysteine synthetase from rat kidney. Methods Enzymol 1985;113:379-90.
40. Sen CK, Tirosh O, Roy S, Kobayashi MS, Packer L. A positively charged alpha-lipoic acid analogue with increased cellular uptake and more potent immunomodulatory activity. Biochem Biophys Res Commun 1998;247:223-8.
41. Sen CK, Roy S, Khanna S, Packer L. Determination of oxidized and reduced lipoic acid using high-performance liquid chromatography and coulometric detection. Methods Enzymol 1999;299:239-46.
42. Sriram K, Shankar SK, Boyd MR, Ravindranath V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J Neurosci 1998;18:10287-96.
43. Suh JH, Shigeno ET, Morrow JD, Cox B, Rocha AE, Frei B, Hagen TM. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid. FASEB J 2001;15:700-6.
44. Suzuki YT, Tsuchia M, Packer L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1991;15:255-63.
45. Thanislass J, Raveendran M, Devaraj H. Buthionine sulfoximine-induced glutathione depletion: its effect on antioxidants, lipid peroxidation and calcium homeostasis in the lung. Biochem Pharmacol 1995;50:229-34.
46. Tirosh O, Sen CK, Roy S, Kobayashi MS, Packer L. Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue. Free Radic Biol Med 1999;26:1418-26.
47. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 1996;264:484-509.
48. Wolz P, Krieglstein J. Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharm 1996;35:369-75.
49. Wolz P, Krieglstein J. Neuroprotective activity of lipoic and dihydro-lipoic acid. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. New York: Marcel Dekker, 1997. p. 205-25.
50. Wullner U, Loschmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L, Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. Neuroreport 1996;7:921-3.
51. Xu DP, Wells WW. Lipoic acid-dependent regeneration of ascorbic acid from dehydroascorbic acid in rat liver mitochondria. J Bioenerg Biomembr 1996;28:77-85.
52. Yamamoto H, Watanabe T, Mizuno H, Endo K, Fukushige J, Hosokawa T, Kazusaka A, Fujita S. The antioxidant effect of DL-alpha-lipoic acid on copper-induced acute hepatitis in Long-Evans Cinnamon (LEC) rats. Free Radic Res 2001;34:69-80.
53. Yoshida I, Sweetman L, Kulovich S, Nyhan WL, Robinson BH. Effect of lipoic acid in a patient with defective activity of pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, and branched-chain ketoacid dehydrogenase. Paediatr Res 1990;27:75-9.
54. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997;46:S62-66.